AZNAstraZenecaRunning, no new patients
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
Esophageal Squamous Cell Carcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 640 (final count)
- Started
- Oct 19, 2020
- Main results expected
- Jun 30, 2027
- Fully finished
- Jun 30, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS) per RECIST 1.1 as assessed by BICR
Measured over: up to approximately 56 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04550260 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC